摘要
目的探究血清免疫球蛋白用于乙型肝炎患者临床检验中的效果。方法将该院2016年8月-2019年8月接收的74例乙型肝炎患者作为研究样本,对所选患者进行检验分析后,依照病情严重程度将24例重型患者设为观察组,另50例普通患者设为试验组;同期选择于该院接受健康体检的60名健康志愿者作为参照组。3组均接受血清免疫球蛋白检验,对比3组检验结果;另外,结合患者治疗情况,分析比较其总胆红素、免疫球蛋白。结果观察组IgG为(17.55±3.12)g/L,IgM为(2.76±0.65)g/L,IgA为(2.64±0.55)g/L,试验组IgG为(2.24±0.50)g/L,IgM为(2.10±0.35)g/L,IgA为(14.24±2.87)g/L均明显高于参照组的(1.72±0.31)g/L、(1.42±0.21)g/L、(11.41±2.02)g/L,差异有统计学意义(t=10.680,P<0.05;t=14.314,P<0.05;t=9.707,P<0.05;t=6.667,P<0.05;t=2.581,P<0.05;t=6.051,P<0.05);其中观察组高于试验组,差异有统计学意义(t=3.119,P<0.05;t=4.515,P<0.05;t=5.688,P<0.05);治疗好转后,患者免疫球蛋白IgA(2.40±0.33)g/L、IgG(14.20±4.00)g/L,IgM(3.15±0.17)g/L与总胆红素(171.23±92.00)μmol/L均低于未好转者的(3.17±0.18)g/L、(16.44±3.19)g/L、(3.81±0.35)g/L、(382.38±141.20)μmol/L,比较差异有统计学意义(t=11.020,P<0.05;t=2.461,P<0.05;t=10.938,P<0.05;t=7.772,P<0.05)。结论免疫球蛋白可作为判定乙型肝炎患者病情的重要指标,总胆红素在乙型肝炎诊断中也有一定的临床价值,建议联合使用,能判定治疗效果,适合临床推广及应用。
Objective To investigate the clinical effect of serum immunoglobulin in hepatitis b patients. Methods 74 hepatitis b patients admitted to the hospital from August 2016 to August 2019 were selected as study samples. After the examination and analysis of the selected patients, 24 severe patients were assigned to the observation group and 50 ordinary patients to the experimental group ac-cording to the severity of the disease. During the same period, 60 healthy volunteers were selected as the reference group. Serum im-munoglobulin test was performed in all three groups and the results were compared. In addition, the total bilirubin and immunoglobu-lin of the patients were compared according to their treatment conditions. Results The observed group IgG was(17.55 ±3.12) g/L, IgM was(2.76±0.65) g/L, IgA was(2.64±0.55) g/L, and the test group IgG was(2.24±0.50) g/L, IgM was(2.10±0.35) g/L, IgA was(14.24±2.87) g/L, which was significantly higher than(1.72 ±0.31) g/L,(1.42±0.21) g/L,(11.41±2.02) g/L of the reference group. The difference was statistically significant(t=10.680, P<0.05;t=14.314,P<0.05;t=9.707, P<0.05;t=6.667, P<0.05;t=2.581, P<0.05;t=6.051, P<0.05);the observation group was higher than the experimental group, The difference was statistically significant( t=3.119,P<0.05;t=4.515, P<0.05;t=5.688, P<0.05);Patients with immunoglobulin IgA(2.40 ±0.33) g/L, IgG(14.20±4.00) g/L, IgM(3.15±0.17) g/L and total bilirubin(171.23±92.00) μmol/L were lower than Among the patients who were improved(3.17 ±0.18) g/L,(16.44±3.19) g/L,(3.81±0.35) g/L,(382.38±141.20) μmol/L, the difference was statistically significant(t=11.020, P<0.05;t=2.461, P<0.05;t=10.938, P<0.05;t=7.772, P<0.05). Conclusion Immunoglobulin can be used as an important indicator to determine the condition of patients with hepatitis b. total bilirubin has certain clinical value in hepatitis b diagnosis.
作者
王保华
WANG Bao-hua(Yanggu County Third People's Hospital,Liaocheng,Shandong Province,252300 China)
出处
《世界复合医学》
2019年第11期35-37,共3页
World Journal of Complex Medicine
关键词
临床检验
免疫球蛋白
乙型肝炎
临床价值
免疫水平
Clinical examination
Immunoglobulin
Hepatitis b
Clinical value
Immune level
